XASXHLS
Market cap633mUSD
Dec 23, Last price
1.40AUD
1D
0.72%
1Q
-17.65%
Jan 2017
-64.43%
Name
Healius Ltd
Chart & Performance
Profile
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through four segments: Pathology, Imaging, Day Hospitals, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands. It operates 2,105 pathology sites; 11 day hospital sites; and 134 imaging sites. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
Income | ||||||||||
Revenues | 1,746,200 2.30% | 1,706,900 -25.43% | 2,288,900 20.42% | |||||||
Cost of revenue | 2,136,400 | 1,612,000 | 1,814,800 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (390,200) | 94,900 | 474,100 | |||||||
NOPBT Margin | 5.56% | 20.71% | ||||||||
Operating Taxes | (14,100) | (17,300) | 122,200 | |||||||
Tax Rate | 25.78% | |||||||||
NOPAT | (376,100) | 112,200 | 351,900 | |||||||
Net income | (645,800) 72.40% | (374,600) -221.66% | 307,900 604.58% | |||||||
Dividends | (34,300) | (98,100) | ||||||||
Dividend yield | 1.75% | 4.18% | ||||||||
Proceeds from repurchase of equity | 179,300 | (5,200) | (388,900) | |||||||
BB yield | -18.12% | 0.27% | 16.57% | |||||||
Debt | ||||||||||
Debt current | 271,300 | 263,000 | 223,700 | |||||||
Long-term debt | 2,503,700 | 2,443,900 | 1,555,300 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 15,200 | 14,400 | 967,800 | |||||||
Net debt | 2,711,700 | 2,584,500 | 1,691,900 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 266,800 | 306,400 | 573,800 | |||||||
CAPEX | (50,900) | (76,100) | (93,500) | |||||||
Cash from investing activities | (63,000) | 67,300 | (401,700) | |||||||
Cash from financing activities | (259,000) | (339,700) | (163,500) | |||||||
FCF | (348,100) | 116,300 | 242,300 | |||||||
Balance | ||||||||||
Cash | 60,100 | 115,300 | 81,300 | |||||||
Long term investments | 3,200 | 7,100 | 5,800 | |||||||
Excess cash | 37,055 | |||||||||
Stockholders' equity | 1,040,700 | 1,506,200 | 1,921,600 | |||||||
Invested Capital | 2,653,800 | 3,249,545 | 3,651,900 | |||||||
ROIC | 3.25% | 10.16% | ||||||||
ROCE | 2.89% | 12.98% | ||||||||
EV | ||||||||||
Common stock shares outstanding | 659,760 | 615,566 | 639,497 | |||||||
Price | 1.50 -52.83% | 3.18 -13.35% | 3.67 -20.73% | |||||||
Market cap | 989,640 -49.44% | 1,957,499 -16.59% | 2,346,953 -25.12% | |||||||
EV | 3,701,340 | 4,541,999 | 4,038,853 | |||||||
EBITDA | (390,200) | 372,100 | 745,300 | |||||||
EV/EBITDA | 12.21 | 5.42 | ||||||||
Interest | 70,800 | 62,300 | 49,000 | |||||||
Interest/NOPBT | 65.65% | 10.34% |